Recherche - Université de Picardie Jules Verne Accéder directement au contenu

Filtrer vos résultats

9 Résultats
authFullName_s : Stephane Nancey

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease

Parambir S. Dulai , Aurélien Amiot , Laurent Peyrin-Biroulet , Vipul Jairaith , Mélanie Serrero , et al.
Alimentary Pharmacology and Therapeutics, 2020, 51 (5), pp.553-564. ⟨10.1111/apt.15609⟩
Article dans une revue hal-03552288v1

Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years

Gilles Boschetti , Stephane Nancey , Fady Daniel , Benjamin Pariente , Eric Lerebours , et al.
Inflammatory Bowel Diseases, 2016, 22 (12), pp.2924-2932. ⟨10.1097/MIB.0000000000000967⟩
Article dans une revue hal-03553388v1
Image document

Prevalence and determinants of fatigue in patients with IBD: a cross-sectional survey from the GETAID.

Aurelien Amiot , Sayma Chaibi , Yoram Bouhnik , Melanie Serrero , Jerome Filippi , et al.
Journal of Crohn's and Colitis, 2023, pp.jjad060. ⟨10.1093/ecco-jcc/jjad060⟩
Article dans une revue hal-04052487v1
Image document

Prevalence of anti-TNF contraindications in Crohn’s disease: A cross-sectional survey from the GETAID

Aurelien Amiot , Philippe Seksik , Jean-Marie Reimund , Maria Nachury , Romain Altwegg , et al.
Digestive and Liver Disease, 2022, 54 (10), pp.1350-1357. ⟨10.1016/j.dld.2022.04.011⟩
Article dans une revue hal-03690498v1

Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study

Mathurin Fumery , Antoine Defrance , Xavier Roblin , Romain Altwegg , Benedicte Caron , et al.
Alimentary Pharmacology & Therapeutics (Suppl), 2022, ⟨10.1111/apt.17358⟩
Article dans une revue hal-03911091v1

The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease

Sara Tadbiri , Maria Nachury , Yoram Bouhnik , Melanie Serrero , Xavier Hébuterne , et al.
Journal of Crohn's and Colitis, 2021, 15 (5), pp.766-773. ⟨10.1093/ecco-jcc/jjaa244⟩
Article dans une revue hal-04007394v1

Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID

Doriane Broussard , Pauline Riviere , Joelle Bonnet , Ginette Fotsing , Aurelien Amiot , et al.
Alimentary Pharmacology and Therapeuthics, 2021, 53 (3), pp.400-409. ⟨10.1111/apt.16176⟩
Article dans une revue hal-03228852v1
Image document

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Edouard Louis , Matthieu Resche-Rigon , David Laharie , Jack Satsangi , Nik Ding , et al.
The Lancet Gastroenterology & Hepatology, 2023, 8 (3), pp.215-227. ⟨10.1016/S2468-1253(22)00385-5⟩
Article dans une revue hal-03947192v1
Image document

Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

Rose Al Bacha , Yoram Bouhnik , Melanie Serrero , Jerome Filippi , Xavier Roblin , et al.
Digestive and Liver Disease, 2023, ⟨10.1016/j.dld.2023.05.008⟩
Article dans une revue hal-04113898v1